Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Data for Deportation
  • Home Births
  • Hantavirus News Roundup
  • RFK Jr.
  • AI in Healthcare

WHAT'S NEW

  • Medicaid Data for Deportation
  • Home Births
  • Hantavirus News Roundup
  • RFK Jr.
  • AI in Healthcare

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, May 1 2017

Full Issue

Rep. Slaughter Offers Bill To Tighten 'Ethics Loopholes' On Congressional Stock Trading

Controversial purchases of stock in an Australian drug company by Reps. Chris Collins (R-N.Y.) and Tom Price (R-Ga.), now the secretary of the Department of Health and Human Services, prompted the move, Rep. Louise Slaughter (D-N.Y.) says. Also on Capitol Hill, Democrats press a bill that would ban "conversion therapy" treatments to change a person's sexual orientation.

The Washington Post: Lawmakers’ Questionable Stock Trades Prompt New Bill

Rep. Louise M. Slaughter introduced a bill Friday to close “ethics loopholes” in a five-year-old law that has failed to stop members of Congress from taking advantage of exclusive stock deals that are not available to the general public. Slaughter (D-N.Y.), a co-author of the 2012 Stock Act, said she decided that amendments to the law are needed because of controversial, discounted stock purchases that were made by Reps. Chris Collins (R-N.Y.) and Tom Price (R-Ga.), now the secretary of health and human services,  in 2015 and 2016. (Kindy, 4/28)

The Washington Post: The Therapeutic Fraud Prevention Act Of 2017 Was Introduced By Democrats In Congress

Democratic lawmakers this week introduced a bill that would ban the practice of “conversion therapy,” treatments that historically have targeted the LGBT community and claim to be able to change a person’s sexual orientation or gender identity. The Therapeutic Fraud Prevention Act of 2017 was introduced Tuesday by Rep. Ted Lieu (D-Calif.), along with Sens. Patty Murray (D-Wash.) and Cory Booker (D-N.J.). About 70 other members of Congress, all Democrats, have said they support the bill, which would allow the Federal Trade Commission to classify conversion therapy and its practitioners as fraudulent. (Wang, 4/27)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 14
  • Wednesday, May 13
  • Tuesday, May 12
  • Monday, May 11
  • Friday, May 8
  • Thursday, May 7
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF